Patents by Inventor Yung-Nien Chang
Yung-Nien Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080103109Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.Type: ApplicationFiled: October 25, 2007Publication date: May 1, 2008Inventors: Paul Hallenbeck, Yung-Nien Chang, Yawen Chiang
-
Publication number: 20080076172Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits trancription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.Type: ApplicationFiled: October 24, 2007Publication date: March 27, 2008Applicant: Cell Genesys, Inc.Inventors: Paul Hallenbeck, Yung-Nien Chang, Yawen Chiang
-
Publication number: 20070086985Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.Type: ApplicationFiled: November 17, 2006Publication date: April 19, 2007Applicant: Cell Genesys, Inc.Inventors: Paul Hallenbeck, Yung-Nien Chang, Yawen Chiang
-
Publication number: 20060121579Abstract: The present invention provides nucleic acid constructs, expression systems, and methods relating to the regulation of gene expression. The invention may be applied to regulate the expression of any coding sequence of interest, including those coding for viral components necessary for the packaging of viral particles.Type: ApplicationFiled: December 13, 2004Publication date: June 8, 2006Inventors: Yung-Nien Chang, Yajin Ni, Boro Dropulic
-
Publication number: 20060002897Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.Type: ApplicationFiled: September 2, 2005Publication date: January 5, 2006Inventors: Paul Hallenbeck, Yung-Nien Chang, Yawen Chiang
-
Patent number: 6835568Abstract: The present invention provides nucleic acid constructs, expression systems, and methods relating to the regulation of gene expression. The invention may be applied to regulate the expression of any coding sequence of interest, including those coding for viral components necessary for the packaging of viral particles.Type: GrantFiled: October 30, 2001Date of Patent: December 28, 2004Assignee: Virxsys CorporationInventors: Yung-Nien Chang, Yajin Ni, Boro Dropulic
-
Publication number: 20040062756Abstract: The present invention provides methods, as well as compositions related thereto, for the efficient transduction of cells using viral vectors. The efficiency of transduction is increased by contacting the cell to be transduced with one or more molecules that bind the cell surface. Contact with a cell surface binding molecule may occur before, after, or simultaneously with contact between the viral vector and the cell. The transduced vectors may be constructed to express a gene of interest, permitting the transduced cells to be used as therapeutic and prophylactic agents.Type: ApplicationFiled: September 16, 2003Publication date: April 1, 2004Inventors: Laurent Humeau, Wei Han, Xiaobin Lu, Vladimir Slepushkin, Mechelle Lesher, Brian Davis, Yung-Nien Chang, Boro Dropulic
-
Publication number: 20040009588Abstract: The invention generally relates to cell-specific expression vectors. It particularly relates to targeted gene therapy using recombinant expression vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional expression vectors and methods for using them. Such vectors are able to selectively replicate in a target cell or tissue to provide a therapeutic benefit in a tissue from the presence of the vector per se or from one or more heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.Type: ApplicationFiled: June 24, 2003Publication date: January 15, 2004Applicant: Genetic Therapy, Inc.Inventors: Yung-Nien Chang, Paul L. Hallenbeck, Carl M. Hay, David A. Stewart
-
Patent number: 6638762Abstract: The invention generally relates to cell-specific expression vectors. It particularly relates to targeted gene therapy using recombinant expression vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional expression vectors and methods for using them. Such vectors are able to selectively replicate in a target cell or tissue to provide a therapeutic benefit in a tissue from the presence of the vector per se or from one or more heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.Type: GrantFiled: November 19, 1997Date of Patent: October 28, 2003Assignee: Genetic Therapy, Inc.Inventors: Yung-Nien Chang, Paul L. Hallenbeck, Carl M. Hay, David A. Stewart
-
Patent number: 6627442Abstract: The present invention provides methods, as well as compositions related thereto, for the efficient transduction of cells using viral vectors. The efficiency of transduction is increased by contacting the cell to be transduced with one or more molecules that bind the cell surface. Contact with a cell surface binding molecule may occur before, after, or simultaneously with contact between the viral vector and the cell. The transduced vectors may be constructed to express a gene of interest, permitting the transduced cells to be used as therapeutic and prophylactic agents.Type: GrantFiled: August 31, 2000Date of Patent: September 30, 2003Assignee: VIRxSYS CorporationInventors: Laurent Humeau, Wei Han, Xiaobin Lu, Vladimir Slepushkin, Mechelle Lesher, Brian Davis, Yung-Nien Chang, Boro Dropulic
-
Publication number: 20030129175Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.Type: ApplicationFiled: December 19, 2002Publication date: July 10, 2003Inventors: Paul L. Hallenbeck, Yung-Nien Chang, Yawen L. Chiang
-
Publication number: 20030118570Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.Type: ApplicationFiled: December 19, 2002Publication date: June 26, 2003Inventors: Paul L. Hallenbeck, Yung-Nien Chang, Yawen L. Chiang
-
Publication number: 20030113296Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.Type: ApplicationFiled: December 19, 2002Publication date: June 19, 2003Inventors: Paul L. Hallenbeck, Yung-Nien Chang, Yawen L. Chiang
-
Publication number: 20030087419Abstract: The present invention provides nucleic acid constructs, expression systems, and methods relating to the regulation of gene expression. The invention may be applied to regulate the expression of any coding sequence of interest, including those coding for viral components necessary for the packaging of viral particles.Type: ApplicationFiled: October 30, 2001Publication date: May 8, 2003Inventors: Yung-Nien Chang, Yajin Ni, Boro Dropulic
-
Patent number: 6551587Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that inhibits transcription of the gene by means of the transcriptional regulatory sequence with this vector, therefore, a target tissue can be selectively treated.Type: GrantFiled: December 15, 1998Date of Patent: April 22, 2003Assignee: Genetic Therapy, Inc.Inventors: Paul L. Hallenbeck, Yung-Nien Chang, Yawen L. Chiang
-
Publication number: 20030012767Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that ihibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.Type: ApplicationFiled: December 15, 1998Publication date: January 16, 2003Inventors: PAUL L. HALLENBECK, YUNG-NIEN CHANG, YAWEN L. CHIANG
-
Patent number: 5998205Abstract: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per se or from heterologous gene products expressed from the vector and distributed throughout the tissue. In such vectors, a gene essential for replication is placed under the control of a heterologous tissue-specific transcriptional regulatory sequence. Thus, replication is conditioned on the presence of a factor(s) that induces transcription or the absence of a factor(s) that ihibits transcription of the gene by means of the transcriptional regulatory sequence with this vector; therefore, a target tissue can be selectively treated.Type: GrantFiled: August 1, 1997Date of Patent: December 7, 1999Assignee: Genetic Therapy, Inc.Inventors: Paul L. Hallenbeck, Yung-Nien Chang, Yawen L. Chiang